Home
Home

NPS Pharmaceuticals

Can These Biotechs Continue to Climb?

Can These Biotechs Continue to Climb?
Motley Fool

Orphan Drug Is Headed Back to Its Parent: NPS Pharmaceuticals, Inc.

Orphan Drug Is Headed Back to Its Parent: NPS Pharmaceuticals, Inc.
Insider Monkey

NPS Buys Back Rights to Gattex From Takeda to Spur Sales

NPS Buys Back Rights to Gattex From Takeda to Spur Sales
Bloomberg

NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It

NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It
Y Charts

3 Drug Launches You Need to Know in 2013

3 Drug Launches You Need to Know in 2013
Motley Fool

Banking on Biotech

Banking on Biotech
CNBC

NPS Pharma: Controversy Over Super-Expensive Orphan Drug Prices

NPS Pharma: Controversy Over Super-Expensive Orphan Drug Prices
The Street

13 Biotech Stock Predictions for 2013

13 Biotech Stock Predictions for 2013
TheStreet.com

A Comprehensive Analysis Of NPS Pharmaceuticals

A Comprehensive Analysis Of NPS Pharmaceuticals
Seeking Alpha

4 FDA Approvals in 1 Day

4 FDA Approvals in 1 Day
Motley Fool